DOD Biotech PCL Statistics

Total Valuation

DOD Biotech PCL has a market cap or net worth of THB 535.99 million. The enterprise value is 352.27 million.

Market Cap	535.99M
Enterprise Value	352.27M

Important Dates

The next estimated earnings date is Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

DOD Biotech PCL has 450.41 million shares outstanding. The number of shares has increased by 3.47% in one year.

Current Share Class	n/a
Shares Outstanding	450.41M
Shares Change (YoY)	+3.47%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	12.46%
Owned by Institutions (%)	19.52%
Float	350.04M

Valuation Ratios

The trailing PE ratio is 16.93.

PE Ratio	16.93
Forward PE	n/a
PS Ratio	0.81
PB Ratio	0.60
P/TBV Ratio	0.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.76, with an EV/FCF ratio of 28.62.

EV / Earnings	-2.21
EV / Sales	0.53
EV / EBITDA	4.76
EV / EBIT	24.36
EV / FCF	28.62

Financial Position

The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.05.

Current Ratio	1.68
Quick Ratio	0.72
Debt / Equity	0.05
Debt / EBITDA	0.62
Debt / FCF	3.74
Interest Coverage	3.87

Financial Efficiency

Return on equity (ROE) is 2.76% and return on invested capital (ROIC) is 0.83%.

Return on Equity (ROE)	2.76%
Return on Assets (ROA)	0.66%
Return on Invested Capital (ROIC)	0.83%
Return on Capital Employed (ROCE)	1.57%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.48
Inventory Turnover	3.16

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -52.02% in the last 52 weeks. The beta is 1.19, so DOD Biotech PCL's price volatility has been higher than the market average.

Beta (5Y)	1.19
52-Week Price Change	-52.02%
50-Day Moving Average	1.27
200-Day Moving Average	1.86
Relative Strength Index (RSI)	38.36
Average Volume (20 Days)	201,790

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DOD Biotech PCL had revenue of THB 662.04 million and -159.33 million in losses. Loss per share was -0.35.

Revenue	662.04M
Gross Profit	223.46M
Operating Income	14.46M
Pretax Income	40.49M
Net Income	-159.33M
EBITDA	71.39M
EBIT	14.46M
Loss Per Share	-0.35

Full Income Statement

Balance Sheet

The company has 223.09 million in cash and 46.06 million in debt, giving a net cash position of 177.03 million or 0.39 per share.

Cash & Cash Equivalents	223.09M
Total Debt	46.06M
Net Cash	177.03M
Net Cash Per Share	0.39
Equity (Book Value)	891.91M
Book Value Per Share	2.00
Working Capital	250.58M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 34.80 million and capital expenditures -22.49 million, giving a free cash flow of 12.31 million.

Operating Cash Flow	34.80M
Capital Expenditures	-22.49M
Free Cash Flow	12.31M
FCF Per Share	0.03

Full Cash Flow Statement

Margins

Gross margin is 33.75%, with operating and profit margins of 2.18% and -24.07%.

Gross Margin	33.75%
Operating Margin	2.18%
Pretax Margin	6.12%
Profit Margin	-24.07%
EBITDA Margin	10.78%
EBIT Margin	2.18%
FCF Margin	1.86%

Dividends & Yields

DOD Biotech PCL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.47%
Shareholder Yield	-3.47%
Earnings Yield	-29.73%
FCF Yield	2.30%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

DOD Biotech PCL has an Altman Z-Score of 2.25. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.25
Piotroski F-Score	n/a